L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

International Journal of Cancer

Volumn 121, Issue 2, 2007, Pages 257-264

  Antonescu, Cristina R ^a   Busam, Klaus J ^a   Francone, Todd D ^a   Wong, Grace C ^a   Guo, Tianhua ^a   Agaram, Narasimhan P ^a   Besmer, Peter ^a   Jungbluth, Achim ^b   Gimbel, Mark ^a   Chen, Chin Tung ^a   Veach, Darren ^a   Clarkson, Bayard D ^a   Paty, Philip B ^a   Weiser, Martin R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Anal; BRAF mutations; KIT; Melanoma; Mucosal; NRAS

Indexed keywords

B RAF KINASE; COMPLEMENTARY DNA; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR;

ADULT; AGED; ANUS TUMOR; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MELANOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANUS NEOPLASMS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MELANOMA; MIDDLE AGED; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLES; TRANSFECTION;

EID: 34250335270     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22681     Document Type: Article

References (24)

1. Nishikawa S, Kusakabe M, Yoshinaga K, Ogawa M, Hayashi S, Kunisada T, Era T, Sakakura T, Nishikawa S. In utero manipulation of coal color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development. EMBO J 1991;10:2111-8.
2. Besmer P. The kit ligand encoded at the murine Steel locus: a pleiotropic growth and differentiation factor. Curr Opin Cell Biol 1991; 3:939-46.
3. Geissler EN, Ryan MA, Housman DE. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 1988;55:185-92.
4. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The prolo-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988;335:88-9.
5. Fleischman RA, Saltman DL, Stastny V, Zneimer S. Deletion of the c-kit protooncogene in the human developmental defect piebald trait. Proc Natl Acad Sci USA 1991;88:10885-9.
6. Montone KT, van Belle P, Elenitsas R, Elder DE. Prolo-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 1997;10:939-44.
7. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992; 52:197-201.
8. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, Sauter G. Prevalence of KIT expression in human tumors. J Clin Oncol 2004;22:4514-22.
9. Willmore-Payne C, Holdcn JA, Tripp S, Layfield LJ. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 2005;36:486-93.
10. Curlin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KM, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-47.
11. Yeh JJ, Shia J, Hwu WJ, Busam KJ, Paty PB, Guillem JG, Coit DG, Wong WD, Weiser MR. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg 2006;244:1012-7.
12. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-90.
13. Turner DJ, Zirvi MA, Barany F, Elenitsas R, Seykora J. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. J Cutan Pathol 2005;32:334-9.
14. Khanna M, Park P, Zirvi M, Cao W, Picon A, Day J, Paty P, Barany F. Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors. Oncogene 1999;18:27-38.
15. Nathanson DR, Culliford ATt, Shia J, Chen B, D'Alessio M, Zeng ZS, Nash GM, Gerald W, Barany F, Paty PB. HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 2003;105:796-802.
16. Nathanson DR, Nash GM, Chen B, Gerald W, Paty PB. Detection of HER-2/neu gene amplification in breast cancer using a novel polymerase chain reaction/ligase detection reaction technique. J Am Coll Surg 2003;197:419-25.
17. Yoshida H, Nishikawa S-I, Okamura H, Sakakura T, Kusakabe M. The role of c-kit proto-oncogene during melanocyte development in mouse. In vivo approach by the in utero microinjection of anti-c kit antibody. Dev Growth Differ 1993;35:209-20.
18. Gutman M, Singh RK, Radinsky R, Bar-Eli M. Intertumoral heterogeneity of receptor-tyrosine kinases expression in human melanoma cell lines with different metastatic capabilities. Anticancer Res 1994;14: 1759-65.
19. Larue L, Dougherty N, Porter S, Mintz B. Spontaneous malignant transformation of melanocytes explanted from Wf/Wf mice with a Kit kinase-domain mutation. Proc Natl Acad Sci USA 1992;89:7816-20.
20. Pache M, Glatz K, Bosch D, Dirnhofer S, Mirlacher M, Simon R, Schraml P, Rufle A, Flammer J, Sauter G, Meyer P. Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch 2003;443:741-4.
21. Chute DJ, Cousar JB, Mills SE. Anorectal malignant melanoma: morphologic and immunohistochemical features. Am J Clin Pathol 2006;126:93-100.
22. Antonescu CR, Sommer G, Sarran L, Tschernvavsky SJ, Riedel E, Woodruff JM, Robson M, Maki R, Brennan MF, Ladanyi M, DeMatleo RP, Besmer P. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329-37.
23. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399-401.
24. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC. Dasatinib (BMS-354825). a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-81.